EPS Diluted (Annual) Chart

View EPS Diluted (Annual) for GILD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Annual) Chart
Start Trial

Historical EPS Diluted (Annual) Data

View and export this data back to 1992. Start Trial.
Date Value
December 31, 2025 6.781
December 31, 2024 0.3825
December 31, 2023 4.503
December 31, 2022 3.639
December 31, 2021 4.933
December 31, 2020 0.0974
December 31, 2019 4.218
December 31, 2018 4.170
December 31, 2017 3.509
December 31, 2016 9.942
December 31, 2015 11.91
December 31, 2014 7.347
December 31, 2013 1.814
December 31, 2012 1.638
December 31, 2011 1.774
December 31, 2010 1.661
December 31, 2009 1.411
Date Value
December 31, 2008 1.049
December 31, 2007 0.8375
December 31, 2006 -0.648
December 31, 2005 0.429
December 31, 2004 0.2475
December 31, 2003 -0.045
December 31, 2002 0.0438
December 31, 2001 0.0312
December 31, 2000 -0.0294
December 31, 1999 -0.0484
December 31, 1998 -0.0577
December 31, 1997 -0.0297
December 31, 1996 -0.0244
December 31, 1995 -0.0516
March 31, 1994 -0.0428
March 31, 1993 -0.0275
March 31, 1992 0.00

Earnings per Share Definition

Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.

Read full definition.

EPS Diluted (Annual) Range, Past 5 Years

View EPS Diluted (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Annual) Benchmarks

View EPS Diluted (Annual) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 15.32
AbbVie, Inc. 2.361
Regeneron Pharmaceuticals, Inc. 41.48
Amgen, Inc. 14.23
Biogen, Inc. 8.789